Orthocell has announced record quarterly revenue of $2.73 million for the June quarter – our fifth consecutive quarter of record revenue growth.
This outstanding 22.8% increase demonstrates the exceptional market response to Orthocell’s flagship products, Striate+™ and Remplir™. This was achieved before any contribution from US Remplir™ sales, which are expected to ramp up during the first half of FY26.
Key Highlights:
- Record quarterly revenue of $2.73 million (up 22.8% from March quarter)
- Fifth consecutive quarter of record revenue
- Compound Quarterly Growth Rate of 9.5% over the last 3 years
- Strong balance sheet with ~A$28.5 million cash and no debt
- Remplirâ„¢ now used by >200 surgeons across >165 hospitals in Australia
- US market expansion accelerating with 14 specialist distributors across 25 states
With FDA clearance achieved and first US surgery completed, Orthocell is perfectly positioned to capture significant market share in the US$1.6 billion nerve repair market.